Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs SNOA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNOA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–2 Matrix Metrics)

SNOA Overall Winner 6-Pillar Tally: BMRA 0 – 5 SNOA (1 Tie) Matrix Metrics: BMRA 2 – 7 SNOA

As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas SNOA carries 51.6/100 (HOLD) at $0.95 (46.1x Forward P/E, -3.3% operating margin).

  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile SNOA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs SNOA
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
SNOA NASDAQ Head-to-Head Winner
Sonoma Pharmaceuticals, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.95
-12.84% 1D
Market Cap $5.6M
TTM Revenue $23M
Forward P/E 46.1x
Beta / 30D Vol 1.27β · 66% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 49.0 Fund 52.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $1.13 · SMA50: $1.19

6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 5 SNOA)

Columns: Metric · BMRA · SNOA
1. Valuation Multiples SNOA
Forward P/E N/M 46.1x
Trailing P/E N/M 46.1x
PEG Ratio N/M 1.08x
EV / Revenue 1.1x 0.2x
2. Growth & Scale SNOA
Revenue Growth (YoY) -8.3% +28.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.3M $23M
Market Cap $6.0M $5.6M
3. Profitability & Quality SNOA
Gross Margin 0.9% 39.2%
Operating Margin -125.2% -3.3%
Net Profit Margin -115.5% -7.6%
Return on Equity (ROE) -113.8% -34.5%
4. Balance Sheet & Cash Flow SNOA
Cash Generation (TTM) -$3.2M -$4.1M
Cash Flow Margin -73.5% -17.6%
Net Cash / Leverage $1.1M Net Cash $1.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SNOA
OpEx & R&D Intensity N/A 42.5% of Rev ($10.0M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (2) vs SNOA (7)
Institutional Metric BMRA SNOA Criterion Row Edge
Market Capitalization
Scale
$6.0M $5.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 46.1x Lower Multiple SNOA
Forward P/E Ratio
Valuation
N/M 46.1x Lower Multiple SNOA
Revenue Growth (YoY)
Growth
-8.3% +28.0% Higher Growth SNOA
Operating Margin (TTM)
Profitability
-125.2% -3.3% Higher Margin SNOA
Net Profit Margin
Profitability
-115.5% -7.6% Higher Margin SNOA
Return on Equity (ROE)
Capital Efficiency
-113.8% -34.5% Higher ROE SNOA
52-Week Range Position
Momentum
5% ($1–$3) 3% ($1–$4) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 1.27β · 66% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 51.6 / 100 (HOLD) Higher Composite SNOA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $23M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 39.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev 1.08x PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$4.1M ($1.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNOA +11.31 pp
BMRA: -26.49% · SNOA: -15.18%
3M Horizon BMRA +11.92 pp
BMRA: -15.0% · SNOA: -26.92%
6M Horizon SNOA +31.79 pp
BMRA: -39.56% · SNOA: -7.77%
1Y Horizon BMRA +27.56 pp
BMRA: -45.6% · SNOA: -73.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue SNOA Revenue BMRA Op. Margin SNOA Op. Margin Margin Leader
FY2019 $10M $20M -46.4% -59.3% BMRA
FY2020 $10M $20M -41.0% -41.2% BMRA
FY2021 $10M $20M -104.2% -18.5% SNOA
FY2022 $20M $10M -24.0% -46.6% BMRA
FY2023 $10M $10M -135.3% -34.4% SNOA
FY2024 $10M $10M -117.6% -36.9% SNOA
FY2025 $10M $10M -96.7% -26.0% SNOA
FY2026 $0M $20M -119.5% -12.6% SNOA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNOA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNOA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SNOA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.6M market capitalization and -3.3% operating margin.
OpEx & R&D Reinvestment 42.5% of Rev ($10.0M)
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs SNOA Key Questions & Quantitative Answers

As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas SNOA carries 51.6/100 (HOLD) at $0.95 (46.1x Forward P/E, -3.3% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile SNOA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SNOA leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with SNOA at +28.0% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (39.2% gross margin, -3.3% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while SNOA shifted +0.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 42.5% of Rev ($10.0M) (0 disclosures) for SNOA.

SNOA screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas SNOA trades at 46.1x Forward P/E, 46.1x Trailing P/E, 1.08x PEG, and 0.2x EV/Revenue (-17.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus SNOA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, SNOA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.27β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.